Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Xanthine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GDA | Q9Y2T3 | 3/20 | 0.82 |
| ▸ | ACHE | P22303 | 1/20 | 0.82 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PNP | P00491 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 2/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Xanthine SCHEMBL3514682 | 1.00 | GDA (0.82) | GDAACHEABL1RIN1ADORA2B | |
| Xanthine SCHEMBL27830253 | 0.98 | GDA (0.79) | GDAACHEABL1RIN1ADORA2B | |
| Xanthine SCHEMBL4965 | 0.91 | GDA (1.00) | GDAACHEABL1RIN1ADORA2B | |
| Xanthine SCHEMBL2352524 | 0.91 | GDA (1.00) | GDAACHEABL1RIN1ADORA2B | |
| Xanthine SCHEMBL29669592 | 0.91 | GDA (1.00) | GDAACHEABL1RIN1ADORA2B | |
| Xanthine SCHEMBL7849418 | 0.89 | GDA (0.96) | GDAACHEABL1RIN1ADORA2B | |
| Xanthine SCHEMBL1507586 | 0.89 | GDA (0.96) | GDAACHEABL1RIN1ADORA2B | |
| Xanthine SCHEMBL31488667 | 0.89 | GDA (0.96) | GDAACHEABL1RIN1ADORA2B | |
| Xanthine SCHEMBL6783299 | 0.89 | GDA (0.96) | GDAACHEABL1RIN1ADORA2B | |
| Xanthine SCHEMBL2454001 | 0.89 | GDA (0.96) | GDAACHEABL1RIN1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 359 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218731-A1 | COMBINATION THERAPIES FOR CANCER TREATMENT | CLEAR CREEK BIO INC (US) | 2022-07-14 | — | — | US | claimed |
| WO-2020236502-A1 | COMBINATION THERAPIES FOR CANCER TREATMENT | Clear Creek Bio, Inc. (US) | 2020-11-26 | — | — | WO | claimed |
| US-20260116994-A1 | RECOMBINANT MONOCLONAL ANTIBODIES AND CORRESPONDING ANTIGENS FOR COLON AND PANCREATIC CANCERS | PREC BIOLOGICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12584099-B2 | Method for preparing cultures of lactic acid bacteria | CHR. HANSEN A/S (DK) | 2026-03-24 | — | — | US | disclosed |
| US-20260015432-A1 | RECOMBINANT MONOCLONAL ANTIBODIES AND CORRESPONDING ANTIGENS FOR COLON AND PANCREATIC CANCERS | PREC BIOLOGICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12460013-B2 | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers | PRECISION BIOLOGICS, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-12344676-B2 | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers | PRECISION BIOLOGICS, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2025105871-A1 | GENE EDITING TREATMENT METHOD AND THERAPEUTIC AGENT FOR RETINITIS PIGMENTOSA | 재단법인 아산사회복지재단 | 2025-05-22 | — | — | WO | disclosed |
| US-20250049753-A1 | METHODS AND COMPOSITIONS FOR DELIVERING MYCOPHENOLIC ACID ACTIVE AGENTS TO NON-HUMAN MAMMALS | OKAVA PHARMACEUTICALS INC (US) | 2025-02-13 | — | — | US | disclosed |
| US-20240368532-A1 | METHOD FOR PREPARING CULTURES OF LACTIC ACID BACTERIA | CHR. HANSEN A/S (DK) | 2024-11-07 | — | — | US | disclosed |
| US-20240343825-A1 | RECOMBINANT MONOCLONAL ANTIBODIES AND CORRESPONDING ANTIGENS FOR COLON AND PANCREATIC CANCERS | PREC BIOLOGICS INC (US) | 2024-10-17 | — | — | US | disclosed |
| WO-1989011538-A1 | PLATELET-SPECIFIC CHIMERIC IMMUNOGLOBULIN | CENTOCOR, INC. (US) | 1989-11-30 | — | — | WO | disclosed |
| WO-1989008716-A1 | NOVEL RECOMBINANT VACCINIA VIRUS EXPRESSION VECTORS AND METHOD OF SELECTING SAME | THE UNITED STATES OF AMERICA, AS REPRESENTED BY TH (US) | 1989-09-21 | — | — | WO | disclosed |
| EP-0322417-A1 | EMPTY VIRAL CAPSID VACCINES | APPLIED BIOTECHNOLOGY, INC. (US) | 1989-07-05 | — | — | EP | disclosed |
| WO-1989004872-A1 | IMMUNOREACTIVE HETEROCHAIN ANTIBODIES | CENTOCOR, INC. (US) | 1989-06-01 | — | — | WO | disclosed |
| WO-1988009181-A2 | MONOCLONAL ANTIBODIES NEUTRALIZING HIV-1 | TANOX BIOSYSTEMS, INC. (US) | 1988-12-01 | — | — | WO | disclosed |
| WO-1988002026-A1 | EMPTY VIRAL CAPSID VACCINES | APPLIED BIOTECHNOLOGY, INC. (US) | 1988-03-24 | — | — | WO | disclosed |
| WO-1988002022-A1 | RECOMBINANT POXVIRUSES | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH OR (AU) | 1988-03-24 | — | — | WO | disclosed |
| EP-0256654-A2 | Chimeric murine/human immunoglobulin specific for tumour-associated 17-1A Antigen | CENTOCOR, INC. (US) | 1988-02-24 | — | — | EP | disclosed |
| US-4550186-A | ANTITUMOR, ANTILIPEMIC, ANTIINFLAMMATORY, AND ANTIARTHRITIC AGENTS | DUKE UNIVERSITY (US) | 1985-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116994-A1 | RECOMBINANT MONOCLONAL ANTIBODIES AND CORRESPONDING ANTIGENS FOR COLON AND PANCREATIC CANCERS | IGSF11, IGLV6-57, VSIG8 | GDA 1840/4885ACHE 4740/4885ABL1 3101/4885 |
| US-20250049753-A1 | METHODS AND COMPOSITIONS FOR DELIVERING MYCOPHENOLIC ACID ACTIVE AGENTS TO NON-HUMAN MAMMALS | CD47, TPMT, HLA-C | GDA 607/4885ACHE 4461/4885ABL1 1667/4885 |
| US-20260015432-A1 | RECOMBINANT MONOCLONAL ANTIBODIES AND CORRESPONDING ANTIGENS FOR COLON AND PANCREATIC CANCERS | VIP, IAPP, RNASE1 | GDA 467/4885ACHE 4109/4885ABL1 3299/4885 |
| US-12584099-B2 | Method for preparing cultures of lactic acid bacteria | LCT, S100A10, RPLP0 | GDA 1191/4885ACHE 4531/4885ABL1 3909/4885 |
| US-20220218731-A1 | COMBINATION THERAPIES FOR CANCER TREATMENT | PCK2, PC, FOLR2 | GDA 1214/4885ACHE 4803/4885ABL1 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.